Delaware Lets Terminally Ill Patients Use Cannabis in Hospitals

Terminally ill medical cannabis patients in Delaware will have the right to use their medication while hospitalized, under a law Gov. Matt Meyer signed on May 21, 2026. Both the Senate and the House passed Senate Bill 226 without a single opposing vote — 21–0 and 38–0, respectively — before it reached the governor’s desk.

Before SB 226, Delaware law did not require hospitals to allow medical cannabis use on their premises, leaving terminally ill registered patients without a guaranteed right of access to their medication during inpatient care. The new law, which takes effect May 21, 2027, requires licensed acute care hospitals to permit qualifying patients to use their cannabis on-site, within a defined framework of safeguards.

What the Law Requires

The framework is built around patient responsibility, not hospital administration. Patients and their caregivers must acquire, store, and administer the cannabis themselves — hospital staff are not involved in handling it. Cannabis must be kept in a locked container at all times while on the premises. Healthcare facility staff must see a copy of patients’ state medical cannabis registry identification cards, and use must be documented in medical records. Hospitals are also required to develop and distribute written policies governing how cannabis is handled in their facilities.

Smoking and vaping are prohibited. Patients will need to rely on non-combustible formats — tinctures, edibles, capsules, and similar products.

The right does not extend to emergency department patients.

Rep. Kamela Smith, who carried the bill in the House, called it “a patient safety bill” during floor debate before the April 2026 vote. She said the stigma surrounding cannabis creates unnecessary barriers for patients already navigating some of the most difficult moments of their lives — and noted that patients are already using cannabis for cancer, chronic pain, and serious illness, with or without hospital accommodation.

Hospitals retain meaningful discretion. They can prohibit use if a physician determines that cannabis would have an adverse impact on a patient’s medical care or is otherwise contraindicated. That’s a clinical carve-out, not a blanket override — the default under the law is that qualifying patients are permitted access.

A Built-In Federal Escape Valve

The most consequential structural feature of SB 226 is what it allows hospitals to stop doing. Sen. Marie Pinkney, the bill’s primary sponsor, built in an explicit federal-funding protection: if a federal regulatory agency, the Justice Department, or the Centers for Medicare and Medicaid Services takes enforcement action against a hospital or issues guidance prohibiting cannabis use in federally funded facilities, the hospital can suspend its compliance with the state law without penalty.

Pinkney addressed the reasoning directly when the Senate passed the bill in March 2026. Cannabis remains a federally controlled substance, and hospitals receiving Medicare and Medicaid funding face real exposure if federal enforcement shifts. The suspension provision means facilities aren’t forced to choose between state patient-rights compliance and federal funding — the state protection steps aside if federal pressure arrives, and can be reinstated if that pressure recedes.

That design encodes a structural tension that every state medical cannabis program has had to navigate. Patient protections under state law sit beneath a federal legal ceiling, and rather than ignore that ceiling, Delaware’s legislators wrote it directly into the statute.

Modeling California — and a Growing Trend

SB 226 is explicitly modeled on a 2021 California law also known as Ryan’s Law, which requires healthcare facilities to allow terminally ill medical cannabis patients to use their medication on-site. Delaware’s version applies the same patient-controlled model and was narrowed to licensed acute care hospitals specifically — the result of an amendment shaped with input from the Medical Society of Delaware and the Delaware Healthcare Association.

Delaware isn’t moving in isolation. Louisiana recently passed a comparable bill extending hospital access for terminally ill cannabis patients, and both measures cleared their respective legislatures with effectively unanimous support, a pattern that suggests the policy concept travels well across state lines.

Delaware’s medical cannabis program is now regulated by the Office of the Marijuana Commissioner, the same body overseeing the adult-use market that launched in August 2025. SB 226 adds a patient-rights layer targeted at the most vulnerable segment of the patient population. Hospitals and their clinical staffs have until May 2027 to draft and implement written policies before the law’s requirements kick in.

The Delaware legislature is also weighing competing proposals to regulate hemp-derived THC products this session — another front in a busy year for cannabis policy in the state.